Philadelphia College of Osteopathic Medicine Annual Progress Report: 2010 Formula Grant

Similar documents
Hematopoietic Progenitor Cell Product Characterization

Inspections, Compliance, Enforcement, and Criminal Investigations

BD MOSAIC h MSC CELL CULTURE ENVIRONMENT DEFINED SERUM FREE

Expansion of Human Mesenchymal Stem Cells Using Corning HYPER Technology Cell Culture Vessels

Challenges for Product Evaluation by Flow Cytometry for Cellular Therapy Product Processing Laboratories

BUILT TO CONCENTRATE. Magellan is an autologous concentration system that delivers concentrated platelets and cells at the point of care.

Adipose rabbit mesenchymal stem cells for the treatment of the chronic scar tissue of the vocal cords

Background. Background. Background. Background. Background 3/4/2013

How You Can Use Stem Cells

Human Bone Marrow Derived Mesenchymal Stem Cell (MSC) Care Manual

GENReports: Market & Tech Analysis

Autologous Infusions Alisha Mussetter Clinical Research Coordinator II Wednesday February 17 th, 2016

FDA Regulatory, Compliance and Policy Developments: 361 HCT/Ps

INTRODUCTION OF BIOCELLULAR REGENERATIVE MEDICINE

Point-of-Care Cell Processing Devices A Manufacturer s Perspective Clinical trials, regulatory compliance, and commercialization.

Expansion of Human Mesenchymal Stem Cells Using Corning HYPER Technology Cell Culture Vessels

Stem Cell Research From Bench to Bedside

Comparability for Advanced Therapy Medicinal Products. Christopher A Bravery

YOUR OWN LIFE

Regenerative Medicine. Speaker Disclosures. What is regenerative medicine? 6/22/2016

NEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY:

A Brief Comparison Of The Various Techniques And Methods For Isolation Of Circulating Tumor Cells (CTC s)

Adipose-Derived Stem Cell Therapy

initial single-cell analysis, with a pragmatic focus on surface markers with the highest potential for

The Ultimate Guide To STEM CELL THERAPY. for Joint Disorders

Sphere Formation (Osteosphere/Sarcopshere) Assay. Department of Microbiology, NYU School of Medicine, New York, USA

G-Rex Instructions for Use

Regulatory science insights into cellular products and practical microscale technologies for their assessment

PRIME-XV Cell Therapy Products by

Getting to the Factory of the Future

G-Rex Instructions for Use

Marrow Cellution. Autologous Bone Marrow Aspiration & Cancellous Bone Graft Harvesting. aspire-medical.eu

Developing Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013

For personal use only

FROM CONCEPT TO PATIENT TREATMENT: A CLINICAL TRIAL OF MESENCHYMAL STROMAL CELLS FOR AMYOTROPHIC LATERAL SCLEROSIS

Liquid. This product is shipped with dry ice. Upon receipt, store it immediately at the temperature recommended below.

User Manual. OriCell TM C57BL/6 Mouse Adipose-derived Mesenchymal Stem Cells With GFP (ADSCs/GFP) Cat. No. MUBMD-01

Supplementary Information. Conversion of vascular endothelial cells into multipotent stem-like cells

The Role of Adult Stem Cells in Personalized and Regenerative Medicine

Pittsburgh Tissue Engineering Initiative Annual Progress Report: 2011 Formula Grant

PRIME-XV Cell Therapy Products by

Double Syringe System Autologous Conditioned Plasma

DEPArray Technology. Sorting and Recovery of Rare Cells

What is a Stem Cell? 1

Cellometer Auto 2000 Cell Viability Counter Optimized Analysis of Primary Cells Cellometer Features of the Cellometer Auto 2000

MARROW CELLUTION INCREASES CONCENTRATIONS OF STEM AND PROGENITOR CELLS IN MARROW ASPIRATION

Outcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL

Genetics Lecture 19 Stem Cells. Stem Cells 4/10/2012

Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach

Assuring Multipotency of human Mesenchymal Stem Cells (hmsc)

Advancing Manufacturing for Advanced Therapies

Regulation of advanced blood cell therapies

Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells. Cell Therapy Liaison Meeting January, 2018

USAMRMC STRATEGIC COMMUNICATION PLAN ARMED FORCES INSTITUTE OF REGENERATIVE MEDICINE (AFIRM)

Inspections, Compliance, Enforcement, and Criminal Investigations

Current Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs)

User Manual. OriCell TM Human Umbilical Cord Blood Mesenchymal Stem Cells. Cat. No. HUXUB-01001

ISCT Telegraft Column: Mesenchymal Stromal Cell (MSC) Product Characterization and Potency Assay Development

Stem Cells 101. Christopher Centeno, M.D. The Centeno-Schultz Clinic Colorado, USA

Adult Stem Cells for Chronic Pain. Dr. John Hughes, DO January 24 th, 2018

Are Biosimilar Cell Therapy Products Possible? Christopher A Bravery

Principles of Immunophenotyping

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

Realizing the Future that Regenerative Medicine Will Open

All quality control test results are reported on a lot specific Certificate of Analysis which is available at or upon request.

Cytomics in Action: Cytokine Network Cytometry

#SIS25th. 25th Annual Meeting Slides

All quality control test results are reported on a lot specific Certificate of Analysis which is available at or upon request.

What is a Stem Cell? Swiss Medica XXI Century S.A. 1

Agenzia Italiana del Farmaco

Cellometer K2. Cellometer K2 Image Cytometer Optimized Analysis of Primary Cells. Image Cytometers. for Cell Counting & Analysis.

FDA s Same Surgical Procedure Draft Guidance Could Stifle Use of Autologous Stem Cell Therapies

Regenerative Medicine and Stem Cell Therapies

Sharing Data: Recovering Registry Addict

Cellular Engineering Technologies (CET) Inc. Product Guide

Lyset BOOST YOUR CELL CULTURE TODAY FOR THE EXPERIMENTS OF TOMORROW

Cytori Therapeutics. (NASDAQ: CYTX) Lazard Capital Markets 8th Annual Healthcare Conference November 16, 2011 Mark E. Saad, Chief Financial Officer

Stem Cells, Regenerative Medicine and cgmp (GTP)

Application Note. Introduction. Kerry Thompson, Jeff Partridge, Paula Flaherty, Susan Qian, and Deepa Saxena

Andrew Finnerty General Manager - CCMI

Mesenchymal Stem Cells

Cross-Linker Modulation to Maintain Phenotype of RGD-Alginate-Embedded Mesenchymal Stem Cells

ANAT 2341 Embryology Lecture 18 Stem Cells

User Manual. OriCell TM Strain C57BL/6 Mouse Adipose-Derived Mesenchymal Stem Cells (ADSCs) Cat. No. MUBMD-01001

Pittsburgh Tissue Engineering Initiative Annual Progress Report: 2010 Formula Grant

T H E R A P Y REGENERATIVE MEDICINE NATURAL EFFECTIVE LIFE-CHANGING

Spray-on stem cells for rapid healing.

Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.CPA.XX Effective Date: Last Review Date: Line of Business: Commercial

User Manual. OriCell TM Human Umbilical Cord Blood Mesenchymal Stem Cells. Cat. No. HUXUB-01001

PCCS Growth Media, Cell Tagging, Cell Separation Final Assignment. Igneris Rosado-Erazo. Panama College of Cell Science

The Healing Of Tibial And Calvarial Defect Using Runx2-transfected Adipose Stem Cells

User Manual. OriCell TM Human Umbilical Cord Mesenchymal Stem Cells. Cat. No. HUXUC-01001

User Manual. OriCell TM Human Umbilical Cord Mesenchymal Stem Cells. Cat. No. HUXUC-01001

Flexible Purecell Select System Enables Protocol Modifications to Optimize Enriched MNC Population for Downstream Applications

Internationally Standardized Terminology for Regenerated Tissue

Immunophenotyping of Peripheral Blood and Bone Marrow Cells by Flow Cytometry *Akanni EO and # Palini A.

TITLE: Regenerative Medicine and Restoration of Joint Function

Cellometer Vision CBA

On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic

Stem Cells: Evidence for Efficacy

Transcription:

Philadelphia College of Osteopathic Medicine Annual Progress Report: 2010 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The Philadelphia College of Osteopathic Medicine received $19,326 in formula funds for the grant award period January 1, 2011 through December 31, 2014. Accomplishments for the reporting period are described below. Research Project 1: Project Title and Purpose Effect of Liposuction Technique on the Viability and Differentiation of Adipose Derived Stem Cells - Tissue engineering and regenerative medicine is a rapidly developing field of research in which new materials and strategies are proposed for the repair of lost or degenerative tissues. A key factor in these strategies is a ready supply of cells to populate these replacement materials. Adipose derived stem cells have been suggested as a source of autologous cells for potential use in numerous therapies. However, while the use of liposuction techniques for the recovery of these cells from adipose tissue has been proposed, to date, no work has shown the desirability of one potential technique over another. We propose to determine the role of liposuction method on the ability to isolate stem cells from fat for tissue engineering purposes. The results of this work should guide reconstructive strategies in the future, significantly impacting the standard of care. Anticipated Duration of the Project 1/1/2011 12/31/2014 Project Overview The primary objective of the project is to determine the role of liposuction method on the ability to isolate stem cells from fat for tissue engineering purposes. We will specifically test the hypothesis that the method by which adipose tissue is recovered during liposuction will impact both the quality and differentiation potential of adipose-derived stem cells. In Specific Aim 1, we will determine the role liposuction technique plays in altering the viability of retrieved stem cells from adipose tissue. Our clinical collaborator will be providing us with material recovered from liposuction procedures. These procedures will utilize one of four different devices. We will examine material from patients treated with SmartlipoMPX, a brand of laser lipolysis; VASER liposelection, a brand of ultrasonic liposuction; the Custom Acoustic Liposuction device, a powered liposuction cannula; and the Body-Jet Liposuction device, a water-jet assisted liposuction device. These devices will be used in isolation and in combination. Philadelphia College of Osteopathic Medicine - 2010 Formula Grant Page 1

Cells will be isolated from recovered material and analyzed for both viability and concentration of stem cells. Viability of isolated cells will be evaluated immediately and normalized by material volume. Percentages of live and dead cells will be evaluated by flow cytometry. The percentage of stem cells among the isolated cells will be determined by examining the expression of three different cell surface markers, CD31, CD34 and CD45, again by flow cytometry. Adipose derived stem cells express CD34, but are negative for CD31 and CD45. In Specific Aim 2, we will confirm the potential fates of adipose-derived stem cells as a function of liposuction technique. Isolated cells will be cultured in fate specific media. Potential of cells to differentiate into one of three different fates will be evaluated. Osteoblastic, chondrocytic and adipocytic cell fates have been chosen as endpoints and will be evaluated using differentiation markers for each cell type. Accumulated data will allow us to compare each technique individually and in combination on the ability to recover stem cells from the aspirated material. In addition, the role of anatomical position, repeated procedures and anesthetic composition on the viability and differentiation potential of recovered stem cells will be examined. Principal Investigator Marina D Angelo, PhD Associate Professor Philadelphia College of Osteopathic Medicine 4170 City Avenue Philadelphia, PA 19131 Other Participating Researchers and Employers Christopher S. Adams, PhD - employed by Philadelphia College of Osteopathic Medicine Victoria Falcone, DO - employed by Physician Body Solutions Expected Research Outcomes and Benefits Much of the current work in the field of tissue engineering and regenerative medicine is focused on the development of material to replace those lost through trauma and aging. In the field of orthopaedics, for example, these approaches have addressed the problem of wholesale bone loss associated with tumor resection or traumatic damage. A primary problem with such strategies is populating the replacement material with viable cells. Replacement by locally derived repair cells is limited by both the supply of such cells and their ability to penetrate the material. Seeding of the material with cells prior to implantation resolves many of those issues, but raises an even more complex question concerning what could be the source of these cells. While donor cells collected from other patients may one day prove to be an adequate strategy, the current standard of care is the use of autologous cells from the patients themselves. With the identification of stem cells in liposuction aspirate, called adipose derived stem cells, a ready supply of these cells appears to have been identified. Therefore, if, in the future, liposuction is undertaken as a first step in a repair scenario, the question arises, what is the ideal method of harvesting adipose tissue, so as to maximize the recovery of adipose derived stem cells? The focus of this project is toward answering that question. We expect that, with the completion of this project, we will be able to advise how to best maximize the recovery of such cells. Philadelphia College of Osteopathic Medicine - 2010 Formula Grant Page 2

Summary of Research Completed In fiscal year 2010-2011 we completed a pilot study utilizing all available lipoaspirate samples collected from our clinical collaborator, Victoria Falcone, DO, that resulted in a wide variety of patient demographics and lipoplasty techniques. In an attempt to limit the variability in the data, we have focused all ensuing studies to a population based on the majority clusters in the pilot study. We have utilized exclusively female samples within an age distribution of the patients demonstrating no significant difference between the ages of any subsets of the lipoaspirate sample population (Figure 1). In a clinical setting, fat banking, or frozen storage of the retrieved lipoaspirate for later isolation of stem cells, has not been tested to determine the effect on stem cell population retrieved following freezing. In this study, we divided our samples with half being isolated immediately ( fresh ) and the second half being isolated one week later ( frozen ). The lipoplasty techniques used by the physician varied depending on the needs of the patient, because this study utilizes medical waste and patients were not recruited for participation. The samples that we received were collected using mainly two techniques: BodyJet and BodyJet with SmartLipo. Cell counter data (ViaCount, Guava, Millipore) demonstrated that cellular debris in the lipoaspirate isolates averages about 20% of the total events for both frozen and fresh samples (Figure 2). A comparison of the viable cell numbers as a percentage of total cells for frozen versus fresh samples demonstrates that the freezing of the lipoaspirate at -80 C for 1 week has no significant effect on the percentage of viable cells isolated from the tissue (Figure 2). Similarly, there is no significant difference in the amount of debris present in the cellular suspension isolated from BodyJet lipoaspirate samples versus BodyJet with SmartLipo samples (Figure 3). In addition, the data indicates that there is a significant difference in the percentage of viable cells contained in lipoaspirate harvested with BodyJet versus lipoaspirate harvested using both BodyJet and SmartLipo technologies (Figure 3). For most cellular suspensions isolated from fresh samples, stem cells cells stained positively for CD34, and negative for CD31 or CD45 account for approximately 1% to 4% of the cells, with a few individual samples outside of that range (Figure 4). CD34+, CD45- cells, as a percentage of the total cells isolated from fresh samples is statistically significant from frozen samples indicating that while the isolation process retrieves viable cells from frozen tissue (Figure 2), a significantly smaller number of the cells being isolated are actually stem cells (Figure 4). For most cellular suspensions isolated from BodyJet and from BodyJet with SmartLipo samples, stem cells account for approximately 1% to 4% of the cells (Figure 5). CD34+, CD45- cells, as a percentage of the total cells, from BodyJet and BodyJet with SmartLipo samples demonstrates no significant difference in the percentage of stem cells retrieved from either set of lipoaspirate samples (Figure 5). Philadelphia College of Osteopathic Medicine - 2010 Formula Grant Page 3

Figure 1: Patient Population Age Distribution 4.5 Sample Distribution 4 Patient Distribution 3.5 3 2.5 2 1.5 1 0.5 0 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 * The blue bars represent the number of samples per age group. In some cases, multiple samples were taken from one patient. The red bars represent the number of patients per age group. The last category, labeled *, is composed of patients/samples that were received by the lab without a recorded age. Philadelphia College of Osteopathic Medicine - 2010 Formula Grant Page 4

Figure 2: Comparison of Fresh and Frozen Samples by Percentage of Debris or Live Cells (A) Debris as a Percentage of Total Events The bar graph shows the average debris as a percentage of total events counted from fresh (white) and frozen (grey) samples. There is no statistically significant difference. (B) Live Cells as a Percentage of Total CellsThe bar graph shows the average events counted as viable cell as a percentage of the total nucleated events from fresh (white) and frozen (grey) samples. There is no statistically significant difference. Philadelphia College of Osteopathic Medicine - 2010 Formula Grant Page 5

Figure 3: Comparison of BodyJet and BodyJet with SmartLipo Samples by Percentage of Debris or Live Cells (A) Debris as a Percentage of Total Events The bar graph shows the average debris as a percentage of total events counted from BodyJet (white) and BodyJet with SmartLipo (grey) samples. There is no statistically significant difference. (B) Live Cells as a Percentage of Total Cells The bar graph shows a statistical difference (p value < 0.05) in the average events counted as viable cell as a percentage of the total nucleated events from BodyJet (white) versus BodyJet with SmartLipo (grey) samples. Philadelphia College of Osteopathic Medicine - 2010 Formula Grant Page 6

Figure 4: Stem Cells as a Percentage of Total Cells: Fresh vs. Frozen (A) The bar graph shows the CD34+,CD45- cells as a percentage of total events counted from fresh (white) and frozen (grey) samples. There is a statistically significant difference (p value < 0.05). (B) The bar graph shows the CD34+,CD31- cells as a percentage of total events counted from fresh (white) and frozen (grey) samples. Philadelphia College of Osteopathic Medicine - 2010 Formula Grant Page 7

Figure 5: Stem Cells as a Percentage of Total Cells: BodyJet vs. BodyJet with SmartLipo (A) The bar graph shows the CD34+,CD45- cells as a percentage of total events counted from BodyJet (white) and BodyJet with SmartLipo (grey) samples. There is no statistically significant difference. (B) The bar graph shows the CD34+,CD31- cells as a percentage of total events counted from BodyJet (white) and BodyJet with SmartLipo (grey) samples. There is no statistical significance. Philadelphia College of Osteopathic Medicine - 2010 Formula Grant Page 8